Adverse drug reactions occur commonly and primarily manifest in a myriad of cutaneous eruptions. The use of drug patch testing in the diagnosis of specific drug eruptions is increasing; however, a standardized approach to this methodology is currently lacking. A review of current literature was performed on the available evidence of patch testing for drugs. This review addresses the use of patch testing for specific cutaneous adverse drug reactions and for specific classes of drugs including antimicrobials, anticonvulsants, antiretrovirals, glucocorticoids, and nonsteroidal anti-inflammatory drugs. In addition, the approach to performing patch testing to drugs in the clinical arena as well as current contraindications for drug patch testing is reviewed.
Get full access to this article
View all access options for this article.
References
1.
AkiyamaM, NakadaT, SuekiH, et al.Drug eruption caused by nonionic iodinated x-ray contrast media. Acad Radiol, 1998; 5(Suppl 1): S159–S161.
2.
RomanoA, GaetaF, ValluzziRL, et al.Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol, 2012; 129(4): 1166–1169.
3.
BourkeJ, CoulsonI, EnglishJ. Guidelines for the management of contact dermatitis: an update. Br J Dermatol, 2009; 160(5): 946–954.
4.
BarbaudA. Drug patch tests in the investigation of cutaneous adverse drug reactions. Ann Dermatol Venereol, 2009; 136(8-9): 635–644.
5.
BarbaudA, Reichert-PenetratS, TrechotP, et al.The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol, 1998; 139(1): 49–58.
6.
BarbaudA, GoncaloM, BruynzeelD, et al.Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis, 2001; 45(6): 321–328.
7.
BrockowK, RomanoA, BlancaM, et al.General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy, 2002; 57(1): 45–51.
8.
FriedmannPS, Ardern-JonesM. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol, 2010; 10(4): 291–296.
9.
AlankoK. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis, 1994; 31(1): 25–27.
10.
AlankoK, StubbS, ReitamoS. Topical provocation of fixed drug eruption. Br J Dermatol, 1987; 116(4): 561–567.
11.
SantiagoF, GoncaloM, VieiraR, et al.Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis, 2010; 62(1): 47–53.
12.
BarbaudA. Drug patch testing in systemic cutaneous drug allergy. Toxicology, 2005; 209(2): 209–216.
13.
BarbaudA, TrechotP, Reichert-PenetratS, et al.The usefulness of patch testing on the previously most severely affected site in a cutaneous adverse drug reaction to tetrazepam. Contact Dermatitis, 2001; 44(4): 259–260.
14.
BarbaudAM, BeneMC, Reichert-PenetratS, et al.Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol, 1998; 134(8): 1040–1041.
15.
GoncaloM, OliveiraHS, MonteiroC, et al.Allergic and systemic contact dermatitis from estradiol. Contact Dermatitis, 1999; 40(1): 58–59.
16.
RomanoA, ViolaM, GaetaF, et al.Patch testing in non-immediate drug eruptions. Allergy Asthma Clin Immunol, 2008; 4(2): 66–74.
17.
SanchezTS, Sanchez-PerezJ, AraguesM, et al.Flare-up reaction of pseudoephedrine baboon syndrome after positive patch test. Contact Dermatitis, 2000; 42(5): 312–313.
18.
BarbaudA, ColletE, MilpiedB, et al.A multicenter study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol, 2013Mar; 168 (3): 555–562.
19.
VaillantL, CamenenI, LoretteG. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis. Arch Dermatol, 1989; 125(2): 299.
20.
WeeJS, WhiteJM, McFaddenJP, et al.Patch testing in patients treated with systemic immunosuppression and cytokine inhibitors. Contact Dermatitis, 2010; 62(3): 165–169.
21.
ElzagallaaiAA, KnowlesSR, RiederMJ, et al.Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf, 2009; 32(5): 391–408.
22.
KanoY, ShioharaT. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am, 2009; 29(3): 481–501.
23.
LinYT, ChangYC, HuiRC, et al.A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol 2012.
24.
CalkinJM, MaibachHI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis, 1993; 29(5): 223–233.
25.
PichlerWJ, TilchJ. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy, 2004; 59(8): 809–820.
26.
GalindoPA, BorjaJ, GomezE, et al.Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol, 2002; 12(4): 299–304.
27.
WolkensteinP, ChosidowO, FlechetML, et al.Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis, 1996; 35(4): 234–236.
28.
LeeAY. Fixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol, 2000; 1(5): 277–285.
29.
NamazyJA, SimonRA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol, 2002; 89(6): 542–550; quiz 550, 605.
30.
AndradeP, GoncaloM. Fixed drug eruption caused by etoricoxib—2 cases confirmed by patch testing. Contact Dermatitis, 2011; 64(2): 118–120.
31.
TorneroP, De BarrioM, BaezaML, et al.Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis, 2004; 51(2): 57–62.
32.
AndradeP, BrincaA, GoncaloM. Patch testing in fixed drug eruptions—a 20-year review. Contact Dermatitis, 2011; 65(4): 195–201.
33.
OsawaJ, NaitoS, AiharaM, et al.Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol, 1990; 17(4): 235–239.
34.
GrandheNP, KaurI, ParsadD, et al.Role of patch testing in antimicrobial drug eruptions. Contact Dermatitis, 2004; 50(4): 259–261.
35.
LammintaustaK, Kortekangas-SavolainenO. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol, 2005; 152(5): 968–974.
ChaabaneA, AouamK, GassabL, et al.Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundam Clin Pharmacol, 2010; 24(4): 429–432.
38.
EndoJO, DavisC, PowellDL. The potential utility of patch testing in identifying the causative agent of morbilliform drug eruptions. Dermatitis, 2011; 22(2): 114–115.
39.
PatriarcaG, D’AmbrosioC, SchiavinoD, et al.Clinical usefulness of patch and challenge tests in the diagnosis of cell-mediated allergy to betalactams. Ann Allergy Asthma Immunol, 1999; 83(3): 257–266.
40.
RomanoA, Di FonsoM, PapaG, et al.Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes. Allergy, 1995; 50(2): 113–118.
41.
ShearNH, MilpiedB, BruynzeelDP, et al.A review of drug patch testing and implications for HIV clinicians. AIDS, 2008; 22(9): 999–1007.
42.
PhillipsEJ, SullivanJR, KnowlesSR, et al.Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS, 2002; 16(16): 2223–2225.
43.
MallalS, PhillipsE, CarosiG, et al.HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008; 358(6): 568–579.
44.
SaagM, BaluR, PhillipsE, et al.High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis, 2008; 46(7): 1111–1118.
45.
GiorginiS, MartinelliC, TognettiL, et al.Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Dermatol Ther, 2011; 24(6): 591–594.
46.
RomanoA, PettinatoR, AndrioloM, et al.Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des, 2006; 12(26): 3373–3381.
47.
LeeAY, ChoiJ, CheyWY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis, 2003; 48(3): 137–139.
48.
CalistruAM, CunhaAP, NogueiraA, et al.Etoricoxib-induced fixed drug eruption with positive lesional patch tests. Cutan Ocul Toxicol, 2011; 30(2): 154–156.
49.
BelliniV, StingeniL, LisiP. Multifocal fixed drug eruption due to celecoxib. Dermatitis, 2009; 20(3): 174–176.
AlonsoJC, OrtegaJD, GonzaloMJ. Cutaneous reaction to oral celecoxib with positive patch test. Contact Dermatitis, 2004; 50(1): 48–49.
57.
LeeJH, ParkHK, HeoJ, et al.Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci, 2008; 23(3): 521–525.
58.
YaziciAC, BazK, IkizogluG, et al.Celecoxib-induced photoallergic drug eruption. Int J Dermatol, 2004; 43(6): 459–461.
59.
ZmudzinskaM, Czarnecka-OperaczM, SilnyW. Contact allergy to glucocorticosteroids in patients with chronic venous leg ulcers, atopic dermatitis and contact allergy. Acta Dermatovenerol Croat, 2008; 16(2): 72–78.
60.
BaeckM, GoossensA. Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis, 2012; 66(1): 38–45.
61.
LepoittevinJP, DriegheJ, Dooms-GoossensA. Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol, 1995; 131(1): 31–37.
